Antibody molecules which bind CD22
AssigneeUcb Biopharma Sprl
InventorsHelene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
Claims7
An antibody molecule comprising a binding domain specific to CD22, wherein the binding domain comprises a heavy chain variable domain (VH) comprising CDR H1, CDR H2, and CDR H3 and a light chain variable domain (VL) comprising CDR V1, CDR V2, and CDR V3 wherein
- CDR H1 is SEQ ID NO:
- 37;
- CDR H2 is SEQ ID NO:
- 48, 49, 50, 51, 52 or 53;
- CDR H3 is SEQ ID NO:
- 65, 66 or 67;
- CDR L1 is SEQ ID NO:
- 73;
- CDR L2 is SEQ ID NO:
- 79;
- and
- CDR L3 is SEQ ID NO:
- 100.
An antibody molecule comprising a VH comprising SEQ ID NO:
- 146.
Dependencies are inferred from the claim text.